The report will provide an outline of the global pharmaceutical industry and an ESG overview of the pharmaceutical industry. Qualitative insights on ESG trends and their impact on pharmaceutical manufacturers are provided, along with a detailed analysis of the pharmaceutical industry supply chain with regard to ESG. The report explains the primary drivers, challenges and trends influencing ESG implementation in the pharmaceutical industry.
Report Includes
- A brief general outlook of the ESG trends in pharmaceutical industry
- Detailed information about ESG-related developments in the pharmaceutical industry and analyses of factors affecting ESG applications
- Discussion of current trends and issues in the pharmaceutical industry, with emphasis on major challenges and opportunities
- Analysis of the whole supply chain of the pharmaceutical industry and its association with ESG
- Information on major causes, and impact of pharmaceutical pollution and a detailed case study related to pharmaceutical pollution
Table of Contents
Chapter 1 Introduction
1.1 What is Environmental, Social and Governance (Esg) Compliance?
1.2 Study Goals and Objectives
1.3 Reasons for Doing this Study
1.4 Scope of Report
1.5 Intended Audience
1.6 Information Sources
1.7 Analyst's Credentials
1.8 Custom Research
1.9 Related Research Reports
Chapter 2 Overview of the Pharmaceutical Industry
2.1 Introduction
2.2 Pharmaceutical Industry Supply Chain
2.2.1 Manufacturing
2.2.2 Distribution
2.2.3 Providers
2.2.4 Customers and Patients
2.3 Esg Deterrents in the Pharmaceutical Supply Chain
Chapter 3 Environmental Impact of the Pharmaceutical Industry
3.1 Introduction
3.2 Major Causes of Pharmaceutical Pollution
3.2.1 Drug Use, Ingestion and Disposal
3.2.2 Healthcare Institutions
3.2.3 Drug Manufacturers
3.2.4 Agriculture and Argo-Products
3.2.5 Local Pharmaceutical Use and Disposal in Humans
3.3 Impact of Pharmaceutical Pollution
3.3.1 Effects on Aquatic Life and Fish
3.3.2 Disrupting Normal Sewerage Process Operations
3.3.3 Drinking Water Impact
3.3.4 Long-Lasting Effects on the Environment
3.3.5 Antibiotic Resistance
3.3.6 Impact on Wildlife
3.4 Growing Focus on Scope 3 Emissions
3.4.1 Case Study on Pharmaceutical Pollution
Chapter 4 Esg in the Pharmaceutical Industry
4.1 Introduction to Esg
4.2 Increasing Adoption of Esg Across Various Industries
4.3 Esg Proposition in Five Critical Ways
4.4 Esg Performance in the Pharmaceutical Industry
4.5 Surge in Investment in Esg in the Pharmaceutical Industry
4.6 Esg Investments by Key Players
4.7 Companies Incorporating Esg into Their Value Chains
4.7.1 Biogen
4.7.2 Collaboration Between Novartis and Gsk in Africa
4.7.3 Amgen
4.7.4 Enabler
Chapter 5 Market Dynamics
5.1 Macroeconomic Trends in the Market for Esg in the Pharmaceutical Industry
5.1.1 Climate Change
5.1.2 Medication Access in Underdeveloped Nations
5.1.3 Drug Pricing and Gouging
5.2 Esg-Related Drivers of the Pharmaceutical Industry
5.3 Esg-Related Challenges for Pharmaceutical Industry
5.4 Esg-Related Opportunities in the Pharmaceutical Industry
Chapter 6 Appendix: Acronyms
List of Tables
Table 1: Net-Zero GHG Commitments by Major Life Sciences Companies
Table 2: Environmental, Social and Governance Factors in the Pharmaceutical Industry
Table 3: ESG Factors in the Pharmaceutical Industry
Table 4: Key Environmental, Social and Governance Issues in the Pharmaceutical Industry
Table 5: ESG Ranking of Pharmaceutical Industry Players, 2022
Table 6: Acronyms Used in This Report
List of Figures
Figure 1: Global Market Shares of the Pharmaceutical Industry, by Region, 2021
Figure 2: Top 10 Global Pharmaceutical Companies, by Revenue, 2021
Figure 3: Pharmaceutical Supply Chain
Figure 4: Level of Adoption of ESG across All Industries
Figure 5: Level of Adoption of ESG across All Industries by Region, 2021 and 2022
Samples
LOADING...
Executive Summary
Environmental, social and governance (ESG) pillars describe the standards and policies that when combined demonstrate an organization’s commitment to functioning sustainably. ESG reporting enables organizations to understand and convey the risks and opportunities associated with their business activities. Businesses may use ESG reporting to create objectives and KPIs, evaluate performance and manage change to make their processes more sustainable and in accordance with the values of their stakeholders. Through sustainability reporting, organizations may understand and share the possibilities and dangers connected with their corporate operations.
ESG performance is typically evaluated using numerical values to assess levels of maturity in terms of environmental impacts, compliance with safety and health requirements, professional behavior as it relates to bribery and corruption, business ethics and policies on critical issues (e.g., modern slavery, human trafficking).
Reasons for Doing This Study:
- This paper is intended to assist pharmaceutical industry decision makers by giving background information to be considered during ESG implementation. Determining the most suitable ESG analysis and investment becomes increasingly vital given the global pharmaceutical market’s dynamism and the ever-changing regulatory framework requirements for pharmaceutical goods.
- This research investigates the ESG framework for pharmaceutical businesses to assist corporations and shareholders in prioritizing strategic moves. The availability of favorable government legislation in many locations, as well as rising environmental consciousness, are factors driving new market prospects. This research examines these changes and their implications for the pharmaceutical industry’s future. The study focuses on the evolving trends, market restraints, drivers and opportunities that are expected to boost ESG investment in the pharmaceutical industry.
